AUM $1.31BER 0.75%NAV $32.85Holdings 10Inception Oct 2014
Price Chart
Key Statistics
Previous Close
$33.65Day Range
$33.12$34.44
52-Week Range
$23.09$36.27
Avg Volume
3.3MDividend Yield
—Expense Ratio
0.75%AUM
$1.31BShares Outstanding
36.5METF Grades
?ETF Grades compare this fund against others in the same category using percentile rankings across six factors. Grades range from A+ (top 5%) to F (bottom 20%). Updated daily.Sector Breakdown
| Sector | Weight % |
|---|---|
| Healthcare | 99.27% |
| Financial Services | 0.49% |
| Cash & Others | 0.24% |
Country Allocation
| Country | Weight % |
|---|---|
| United States | 84.83% |
| Switzerland | 7.86% |
| Other | 3.59% |
| United Kingdom | 2.91% |
| Germany | 0.81% |
Fund Information
- Issuer
- ARK
- Category
- Healthcare
- Inception Date
- Oct 30, 2014
- Exchange
- BATS
- Description
- ARKG is an actively managed Exchange Traded Fund (ETF) that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors that are relevant to the Fund’s investment theme of the genomics revolution.
Similar ETFs
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund issued by ARK that launched on Oct 30, 2014. It currently manages $1.31B in assets under management. The fund charges an expense ratio of 0.75%. The fund holds 10 securities in its portfolio. It falls under the Healthcare category.
Top 10 holdings represent 61.1% of the fund
| Rank | Symbol | Name | Weight % | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | TWST | TWIST BIOSCIENCE CORP | 9.76% | 1,639,192 | $121.4M |
| 2 | TEM | TEMPUS AI INC-CL A | 7.88% | 1,975,468 | $98.0M |
| 3 | CRSP | CRISPR THERAPEUTICS AG | 7.57% | 1,875,285 | $94.2M |
| 4 | TXG | 10X GENOMICS INC-CLASS A | 6.65% | 2,845,656 | $82.7M |
| 5 | ABSI | ABSCI CORP | 5.59% | 10,680,421 | $69.5M |
| 6 | PSNL | PERSONALIS INC | 5.45% | 7,193,252 | $67.8M |
| 7 | ILMN | ILLUMINA INC | 4.71% | 352,460 | $58.6M |
| 8 | GH | GUARDANT HEALTH INC | 4.68% | 445,085 | $58.3M |
| 9 | BEAM | BEAM THERAPEUTICS INC | 4.66% | 1,971,969 | $58.0M |
| 10 | NTRA | NATERA INC | 4.16% | 235,762 | $51.7M |
| 11 | VCYT | VERACYTE INC | 3.28% | 860,892 | $40.8M |
| 12 | CDNA | CAREDX INC | 3.20% | 1,684,697 | $39.9M |
| 13 | NTLA | INTELLIA THERAPEUTICS INC | 2.94% | 2,960,576 | $36.6M |
| 14 | RXRX | RECURSION PHARMACEUTICALS-A | 2.85% | 11,259,450 | $35.5M |
| 15 | ADPT | ADAPTIVE BIOTECHNOLOGIES | 2.75% | 1,828,223 | $34.2M |
Detailed Returns
| Period | Return | ETF |
|---|---|---|
| 1D | -0.49% | |
| 1W | +0.97% | |
| 1M | +18.90% | |
| 3M | +26.06% | |
| 6M | +15.45% | |
| YTD | +14.70% | |
| 1Y | +39.92% | |
| 3Y | -4.91% | |
| 5Y | -60.88% |
Moving Averages
20-Day MA
$32.31
Above 20-Day MA50-Day MA
$30.57
Above 50-Day MA200-Day MA
$29.39
Above 200-Day MAPrice with Moving Averages
Support & Resistance
52-Week High
$36.27
Current Price
$33.49
52-Week Low
$23.09
$23.09$36.27
Current Yield
—
Annual Dividend
$2.4964
Frequency
1x/year
Last Ex-Date
Dec 29, 2021
Dividend History
| Ex-Date | Amount | Pay Date |
|---|---|---|
| Dec 29, 2021 | $0.3824 | Dec 31, 2021 |
| Dec 29, 2020 | $0.7901 | Dec 31, 2020 |
| Dec 27, 2019 | $1.0539 | Dec 31, 2019 |
| Dec 27, 2018 | $0.2700 | Dec 31, 2018 |
| Dec 27, 2018 | $0.1963 | Dec 31, 2018 |
| Dec 27, 2017 | $0.1927 | Dec 29, 2017 |
| Dec 27, 2017 | $0.1350 | Dec 29, 2017 |
Dividend Payments Over Time
Category Comparison
| Metric | ARKG | Healthcare(176 ETFs) | Innovation(5 ETFs) |
|---|---|---|---|
| Fund Info | |||
| Expense Ratio | 0.75% | 0.61% | 0.75% |
| AUM | $1.31B | $910.0M | $2.73B |
| Dividend Yield | — | 3.35% | 0.72% |
| Avg Volume | 3.3M | 275.1K | 2.4M |
| Holdings | 10 | 99 | 19 |
| Performance | |||
| 1-Month Return | +12.96% | +1.77% | -0.85% |
| 6-Month Return | +7.38% | +3.26% | -5.01% |
| YTD Return | +15.53% | +3.61% | +0.81% |
| 1-Year Return | +37.91% | +24.59% | +20.66% |
Compare with Another ETF
Search for an ETF to compare with ARKG:
FREE DOWNLOAD
The Beginner's Guide to ETFs
20 pages. Zero fluff. Everything you need to start investing in ETFs.
No spam. Unsubscribe anytime.